-
Mashup Score: 14Hematopoiesis - 5 day(s) ago
Hematopoiesis is a quarterly collection of articles written by and for trainees, and curated by the ASH Trainee Council.
Source: www.hematology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1October - 23 day(s) ago
Provided to YouTube by NAXOS of AmericaOctober · North Texas Wind SymphonyNorth Texas Wind Symphony: Passions℗ 2005 KlavierReleased on: 2005-01-01Composer: E…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 50
PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate. We performed uni- and multivariable (MVA) Cox regression stratified by management to select factors for the lymphocyte-predominant international prognostic score (LP-IPS) validated by five-fold cross-validation. RESULTS We identified 2,243 patients with a median age of 37 years (IQR, 23-51). The median follow-up was 6.3 years (IQR, 3.4-10.8). Most had stage I to II (72.9%) and few B symptoms (9.9%) or splenic involvement (5.4%). IAP was scored
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
A huge congratulations to Drs. @michaelsbinkley & @JamieFlerlage and the entire @glow_nlphl team on publication of an NLPHL-specific prognostic score (LP-IPS) in @JCO_ASCO. Deeply grateful to have participated in this high-impact study! #lymsm #NLPHLsm https://t.co/ogQ7qHag7N https://t.co/lHJXdEP2g9
-
-
Mashup Score: 56Mixed-Methods Study of End-of-Life Experiences of Patients With Hematologic Malignancies in Social Hospice Residential Home Care Settings - 2 month(s) ago
PURPOSE Hospice is underutilized by patients with hematologic malignancies (HM), and when patients are referred, they are typically more ill, hospitalized, and with shorter length of stay (LOS) than patients with solid tumors (ST), limiting research about home hospice care experiences of patients with HM. In this mixed-methods study, we examined the hospice experiences of patients with HM who died at residential care homes (RCHs), home-based settings in which volunteer caregivers and hospice staff provide end-of-life (EOL) care under the social hospice model. METHODS We queried a registry of 535 hospice patients who died at RCHs between 2005 and 2020 that included quantitative medication administration data as well as qualitative data from hospice intake forms and written volunteer caregiver narratives. Qualitative data were analyzed by collective case study methodology. Quantitative comparisons of LOS and liquid morphine use were performed with matched patients with ST. RESULTS The re
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Our study of home hospice experiences for blood cancer patients is now published @JCOOP_ASCO. We found unique symptom burden, hospice needs, & use of cancer-directed palliative treatments. Wonderful to collaborate with Dr. Weisse @UnionCollege. #hpm #hapc https://t.co/kDIjO23I7E https://t.co/m5swYERmz1
-
-
Mashup Score: 32“What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients | NEJM - 2 month(s) ago
Perspective from The New England Journal of Medicine — “What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27“What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients | NEJM - 2 month(s) ago
Perspective from The New England Journal of Medicine — “What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 24“What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients | NEJM - 2 month(s) ago
Perspective from The New England Journal of Medicine — “What’s Lymphoma?” — Risks Posed by Immediate Release of Test Results to Patients
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2BISON-PRO Quality of Life Study - 2 month(s) ago
A prospective repository of longitudinal, real-world patient-reported outcomes (PRO) and quality of life data for patients with blood disorders.
Source: bison-pro.orgCategories: General Medicine News, Hem/OncsTweet-
Of course we have branded gear for our BISON-PRO Quality of Life Study! We're collecting longitudinal patient-reported outcomes surveys from folks with blood disorders @CUAnschutz @uchealth. Learn more about the @CUCancerCenter study at https://t.co/BhuYULJjic. #qualityoflife https://t.co/ATSgzShU9b
-
-
Mashup Score: 13Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas - 2 month(s) ago
Abstract. Patients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen re
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 118Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas - 3 month(s) ago
Abstract. Patients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen re
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
Editing an upcoming special episode of the @ASH_hematology Hematopoiesis podcast for #PrideMonth! 🏳️🌈🏳️⚧️ Stay tuned over at Hematopoiesis, the ASH Trainee Council publication by and for hematology trainees: https://t.co/meBp2i8Ul6 https://t.co/j1GPgp0Xv1